Addressing Social Drivers of HIV/AIDS
2009-09-09 - English
available!

Effect of recombinant interleukin-2 (IL-2) on clinical outcomes in patients with a CD4+ T-cell count of >300/mm3: Primary results of the ESPRIT study
2009-09-09 - English

Effect of recombinant interleukin-2 (IL-2) on clinical outcomes in patients with CD4+ T-cell count 50 to 299/mm3: Primary results of the SILCAAT study
2009-09-09 - English

After viewing this presentation, the participant will be able to:
- Understand the purpose of this immunotherapy trial
- Understand the trial methodology behind a clinical end point study
- Understand the effects of recombinant interleukin-2 on CD4+ T-cell counts and clinical endpoints

Combined analysis of the primary results of the evaluation of proleukin in a randomised international study (ESPRIT) and subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCA
2009-09-09 - English
available!

No decay in HIV-infected naïve CD4+T-cells following antiretroviral therapy (ART): A persistent long term reservoir
2009-09-09 - English

Biological determinants of immune reconstitution following highly-active antiretroviral therapy (HAART)
2009-09-09 - English

Markers of inflammation, coagulation and renal function in HIV-infected adults in smart and in two large population-based studies, Cardia and Mesa
2009-09-10 - English

After viewing this presentation the participant will be able to discuss:
- The levels of four biomarkers (hsCRP, IL-6, D-dimer and cystatin-C) in patients with HIV compared to the general population
- The effects of HIV and antiretroviral therapy on these markers

Predictors of initial episode bacterial Pneumonia in ESPRIT
2009-09-10 - English

After viewing this presentation, the participant will be able to:
- Identify risk factors associated with initial episode bacterial pneumonia in ESPRIT

High levels of user acceptability and cytological abnormalities in self collected anal swabs among HIV-infected men who have sex with men in Sydney
2009-09-10 - English

After viewing this presentation the participant will be able to discuss:
- Results from the Blokes with Anal Squamous Intraepithelial Lesions (BASIL) study
-The level of user acceptability for self collected anal cytology swabs
-The level of anal cytological abnormalities in a cohort of HIV+MSM in Sydney

The changing nature of antiretroviral treatment failure
2009-09-10 - English

After viewing this presentation the participant will be able to discuss:
- Highlights from the U.S. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
- New data on switching therapies
- Deep salvage therapies
- Agents that promote CD4+ recovery

Cardiovascular Disease - How Should it Affect Antiretroviral Therapy?
2009-09-10 - English

After viewing this presentation, the participant will be able to:
- Understand the epidemiology of cardiovascular disease in HIV-infected adults
- Understand the role of surrogate markers in predicting cardiovascular risk in HIV-infected adults
- Understand the evidence underlying current recommendations in the Australian antiretroviral guidelines pertaining to cardiovascular disease

Tetrapanins in monocytes and macrophages and their role in HIV-1 infection
2009-09-10 - English

CCL19 leads to enhanced nuclear import of HIV in resting CD4+ T-cells: a path to establishing latent HIV infection in vivo
2009-09-10 - English

The novel HDAC inhibitors Metacept-(MCT)-1 and MCT-3 have potent activity on HIV-1 transcription in latently infected cells
2009-09-10 - English

Immune-based therapies for HIV infection: where might this be heading now?
2009-09-11 - English

After viewing this presentation, the participant will be able to:
- Identify recent developments in immune-based therapeutics for HIV disease
- Address the fundamental challenges with this approach to treatment
- Identify niche areas where immune based therapies might have utility

Immune Responses in Co-infection
2009-09-11 - English

After viewing this presentation, the participant will be able to:
- Understand the scope of coinfection in persons infected with HIV, the complexity of the interaction and the limitation of currently available studies’ results
- Understand the key concepts of immune...(more)

A Lifetime of HIV in Papua New Guinea: 1986 to Today
2009-09-11 - English

Lack of correlation at the lower limit of detection of three commercially available viral load assays for the quantitation of HIV-1 RNA
2009-09-11 - English

The adaptation of the low cost Cavidi Exavir(TM) load RT assay for use with dried plasma spots to measure HIV-1 viral load in resource limited settings
2009-09-11 - English

The use of dried blood spots for HIV-1 drug resistance testing within resource limited settings
2009-09-11 - English

An HIV-1 integrase genotyping assay for the detection of drug resistance mutations
2009-09-11 - English

Using photographed HIV rapid tests in a pilot EQAS
2009-09-11 - English

HIV Prevention for Gay Men in the U.S.
2009-09-11 - English
available!

Qualitative features of an effective immune response to HIV
2009-09-11 - English

After viewing this presentation, the participant will be able to:
- Understand the prevalence and demographics of patients with durable control of HIV
- Understand the possible host or viral factors involved in immunologic control of HIV
- Discuss our current understanding of how the CD8+ T cell response likely mediates immunologic control and the ramifications for vaccines for HIV